Biosion Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
0
Ending by 2030
May 2038
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Feb 28, 2027The maintenance fee for Antibodies Binding SIGLEC15 and Uses Thereof (US 11,739,147) comes due Feb 28, 2027. Unpaid by Aug 30, 2027, it lapses early.
Recent changes
- 3 of the patents on this record were granted since Aug 16, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,390,685 | ErbB2 antibodies and uses therefore In force · From the USPTO record | In force | From the USPTO record | |
| US 11,739,147 | Antibodies Binding SIGLEC15 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,649,789 | Antibodies Binding SIGLEC15 and Uses Thereof In force · Medium confidence | In force | Medium confidence | |
| US 12,503,517 | Antibodies binding CD40 and uses thereof In force · From the USPTO record | In force | From the USPTO record | |
| US 12,559,565 | Antibodies Binding CTLA4 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,479,912 | Monoclonal antibodies which bind thymic stromal lymphopoietin (TSLP), encoding polynucleotides thereof and methods of use thereof to treat diseases In force · From the USPTO record | In force | From the USPTO record | |
| US 12,715,931 | Nanobodies Binding TROP2 and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,679,900 | Antibodies Binding Rankl and Uses Thereof In force · High confidence | In force | High confidence | |
| US 12,723,082 | Monoclonal Antibodies Which Bind PD-1, Encoding Nucleotides Thereof and Method of Use Thereof to Treat Cancer, Infectious Disease and Inflammatory Disease In force · High confidence | In force | High confidence | |
| US 12,703,763 | Antibodies Binding C5 and Uses Thereof In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 2 patents in force now held by others. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
4 pending · 2 no status recorded